In the realm of veterinary medicine, bacterial infections stand as formidable adversaries, casting a long shadow of economic losses and endangering the health of livestock and companion animals alike. This review embarks on a journey to explore innovative strategies in the fight against these infections, with a particular focus on cold plasma (CP) technology. To illuminate the path forward, let us first cast a wider net, acknowledging the diverse landscapes in which CP’s potential can flourish.

Bacterial infections, triggered by a multitude of pathogenic species, afflict animals across the spectrum, from livestock to beloved pets. Among the bacterial protagonists are Campylobacter spp., Salmonella spp., Staphylococcus spp., Streptococcus spp., Pseudomonas aeruginosa, Escherichia coli, Bacillus spp., and Actinobacillus spp. (1). These microbes have etched their presence within the animal kingdom, causing ailments that resonate through various species.

For instance, Campylobacter spp., a group of gram-negative bacteria, orchestrate gastrointestinal turmoil in a wide array of domesticated animals, spanning cattle, chickens, turkeys, pigs, sheep, dogs, and cats (1). Similarly, the shadow of Salmonella spp. looms large, casting its influence over humans and a menagerie of animals, including poultry, pigs, cattle, horses, cats, and dogs (2) Staphylococcus species establish their dominion on skin and mucous membranes, ushering in mastitis among dairy cows, a condition that exacts significant tolls on the dairy industry. Notably, Staphylococcus aureus, E. coli, and various streptococcal species, such as Streptococcus uberis and Streptococcus agalactiae (3), are principal actors in this costly drama (3). Meanwhile, Staphylococcus pseudintermedius orchestrates its narrative, inflicting skin, ear, and tissue infections in cats and dogs (4–6). A concerning twist in this tale is its zoonotic (7, 8) nature, posing a threat to human health (7, 8). Moreover, the disconcerting revelation that approximately 97.8% of methicillin-resistant S. pseudintermedius (MRSP) strains defy multiple antibiotics raises alarms within the veterinary realm (9, 10).

The opportunistic P. aeruginosa, resident on human and mammalian skin and mucous linings, casts its influence on pets like dogs and cats. It paints a canvas of diverse afflictions, ranging from skin and systemic infections (11) to ulcers, papules (12), ear infections (13), eye inflammations (14), sinus (15) issues, dental abscesses (16), and gum diseases (17).

In the case of E. coli, typically a benign member of animal microbiota, certain strains wield the power to unleash severe illnesses. Among them, enterotoxigenic E. coli (ETEC) infection emerges as the prevalent face of colibacillosis, primarily affecting young animals, notably pigs and calves (18) Bacillus subtilis, residing within the Bacillus genus, is implicated in food poisoning and associated with bovine mastitis and ovine abortion (19). Lastly, Actinobacillus species, gram-negative bacteria, stand accused of inciting diverse animal diseases (20).

In the face of these bacterial adversaries, veterinary medicine has long relied on the administration of broad-spectrum antibiotics. These antimicrobial agents, ubiquitous in procedures such as umbilical cord cutting, tail docking, vaccination courses, and castration, seek to mitigate the risk of infection by confronting stress and potential pathogens (21) in animals. However, a shadow looms over this practice in the form of antimicrobial resistance (AMR).

AMR, a global crisis recognized by the World Health Organization, extends its reach not only to human health but also to animals, domestic and wild, and the environment (22). The misuse and overuse of antimicrobial drugs in animal feed facilitate the emergence and dissemination of resistant bacterial strains (23, 24). This alarming trend has birthed a new era, characterized by the ascent of multi-drug resistant (MDR) pathogens and the prevalence of biofilms in food sources (22).

The battlefront of AMR primarily revolves around gram-negative pathogens and their production of β-lactamases, undermining the efficacy of β-lactam antibiotics, essential for treating both human and animal infections (25). Furthermore, microbial communities, known as biofilms, have emerged as a key player in AMR, offering sanctuary to pathogens on various surfaces, living and non-living (26).

As the arsenal of effective antibiotics dwindles, the susceptibility of both animals and humans to infections experiences a resurgence. In the current landscape, the emergence of antibiotic-resistant pathogenic bacteria, such as Klebsiella pneumoniae, Acinetobacter baumannii, and P. aeruginosa, paints a concerning picture (27). This escalating dilemma underscores the need for urgent action. The cunning propensity of these pathogens to form biofilms further compounds the challenge, intensifying concerns about food safety and the proliferation of antibiotic resistance (28). This complex issue demands a comprehensive approach, calling upon the scientific community to seek innovative solutions. In this critical juncture of combating MDR pathogens and biofilms, cold plasma (CP) technology emerges as a beacon of hope (29, 30).

To effectively design and optimize CP devices for applications involving microbial inactivation, it is crucial to have a comprehensive understanding of how various factors influence the antimicrobial efficacy of CP. The key factors that significantly impact CP’s effectiveness include: (i) type of CP device: CP devices can be categorized into three main types: direct CP, indirect CP, and hybrid CP. (ii) Gas composition and flow rate: the composition of the gas used in CP, as well as the flow rate at which it is supplied, plays a critical role in determining its antimicrobial efficacy. (iii) Changes in source frequency, voltage, and power: alterations in the frequency, voltage, and power settings of the CP source can affect its ability to inactivate microorganisms. (iv) Changes in the safe distance for CP treatment: the distance between the CP source and the object being treated can impact the microbial inactivation efficiency. Finding the optimal safe distance is important for effective treatment. (v) CP treatment time: the duration of exposure to CP is an essential factor in determining its antimicrobial effectiveness. Longer treatment times may result in improved inactivation, but there is a need to balance treatment duration with practical considerations. (vi) Initial concentration of microorganisms: the initial concentration of microorganisms present on the treated object can influence the efficacy of CP treatment. Higher initial microbial loads may require longer or more intense CP exposure for effective inactivation. Direct CP involves one of the electrodes being part of the electrical circuit of the treated object, which can increase temperature. Examples of direct CP methods include corona discharge, DBD volume, and spark discharge. Understanding and optimizing these factors will contribute to the development of efficient CP devices for microbial inactivation applications.

Indirect CP involves the transfer of plasma generated between two electrodes to the treated object through diffusion and convection mechanisms. Various studies have noted differences in antimicrobial effectiveness between direct and indirect CP treatments. In the case of S. aureus, the direct CAP treatment exhibited a larger inactive zone compared to the indirect CP treatment (54). Moreover, when treating P. aeruginosa, both N₂ CP and direct air CP treatments achieved a 6 log reduction in colony-forming units (CFU) within 60 s. However, in the case of indirect treatment, a 4 log CFU reduction was achieved for N₂ CP, and a 5 log CFU reduction was achieved for air CP within the same treatment time (55). Gas plays a crucial role in CP discharge production. Typically, gases like Ar, He, air, N₂, O₂, or their mixtures are used for igniting plasma discharges in CP devices. Some studies have only focused on the impact of gas flow, revealing no significant effect (54, 56–58).

Limited research has addressed the impact of variations in gas flow rate on the effectiveness of CP in eliminating microbes. When the helium (He) gas flow rate was increased from 10 liters per minute (lpm) to 14 lpm, the survival count decreased from 5 × 10⁸ colony-forming units per milliliter (CFU/mL) to 6 × 10² CFU/mL for E. coli and from 5 × 10⁸ CFU/mL to 7 × 10³ CFU/mL for S. aureus. This reduction could be attributed to an elevated concentration of active species within CP due to the increased flow rate. In a study conducted by Das et al. (59), raising the power of the cold atmospheric plasma jet (CAPJ) from 0.15 W to 1.6 W demonstrated a decreased likelihood of methicillin-resistant S. aureus (MRSA) biofilm formation. This outcome can be attributed to a higher flux of chemical species at greater frequencies and power, as suggested by Sharma et al. (60) and Wiegand et al. (61). In terms of the CP microjet, 13.56 MHz radiofrequency exhibited superior E. coli inactivation compared to the lower frequency of 50 kHz. However, similar antimicrobial effects as radiofrequency can be achieved at lower frequencies by increasing the voltage, as indicated by Kim et al. (56).

The distance between the nozzle of the CAPJ and the sample is a crucial factor that impacts the effectiveness of CP in combating microbes. Studies by Sharma et al. (62) and Shouzhe and Jinpyo (63), have shown that increasing the exposure distance leads to a decrease in the antimicrobial effect. For example, when the exposure distance was increased from 0.5 cm to 2 cm in the case of air CAPJ, Pedroni et al. (64) observed a reduction in the log colony-forming unit (CFU) reduction value from 2.5 to approximately 1.2. Therefore, the decline in CP’s antimicrobial activity with an extended exposure interval, as reported by Pedroni et al. (64) and Shouzhe and Jinpyo (63), may be attributed to a decrease in the concentration of active species during CP, as suggested by Lotfy et al. (65).

Additionally, the timing of exposure to CP also plays a significant role. When considering a fixed exposure interval in CAPJ, the duration of CP exposure required to achieve the same log reduction of B. subtilis is shorter in Ar + O₂ CP compared to He + O₂ CP. Guimin et al. (66) observed that in the case of argon CAPJ, the lethal log volume (KLV) reached 5.38 after 90 s of CP treatment for S. aureus and 5.36 after 60 s of CP treatment for E. coli.

The enhanced effectiveness of CP against microorganisms may be attributed to the interaction between active species within CP and microorganisms. This interaction intensifies with longer exposure times, resulting in a greater lethal impact. Another contributing factor is the chemical activity present in the growth environment, which ultimately influences the size of the inhibition zone. For instance, when the concentration of E. coli was raised from 102 CFU/mL to 105 CFU/mL, the CP treatment time increased from 30 s to 120 s. Similarly, elevating the concentration of S. aureus from 102 CFU/mL to 105 CFU/mL required a longer CP treatment time of 45 s to 90 s. In a study by Deng et al. (67), a 3 log CFU reduction was achieved for B. subtilis exposed to CP for 200 s and 360 s, respectively, when the initial concentrations were 106 CFU/mL and 109 CFU/mL. Hence, increasing the initial concentration of microorganisms necessitates a longer treatment time with CP, as indicated by Lee et al. (68).

CP has been shown to have various effects on bacteria, ultimately leading to cell destruction (69). The primary impacts encompass damage to the bacterial cell membrane, intracellular protein damage, and direct DNA damage, as highlighted by Niedźwiedź et al. (70). The presence of loaded particles, such as ions and electrons, gives rise to an electrostatic field that permeates the bacterial cell wall, resulting in the breakage of chemical bonds, erosion, and the formation of lesions and openings in the membranes. Additionally, these particles facilitate the entry of plasma toxic compounds into the bacterial cell, intensifying the destructive process, as stated by Olatunde et al. (71). Furthermore, proteins and bacterial DNA are directly affected by oxidative stress, as emphasized by Winter et al. (72). Reactive oxygen radicals induce significant oxidative stress, leading to lipid-oxygenation, loss of cellular cytoplasm and proteins, and oxidative DNA damage (Figure 2). This ultimately culminates in cell death when the repair mechanism becomes overwhelmed. Lastly, Winter et al. (72) illustrated in Figure 1 that before inactivation, cells undergo morphological and chemical changes.

Biofilms are communities of bacteria that flourish in various environments by attaching to solid surfaces and creating an extracellular matrix comprised of polysaccharides, lipids, proteins, and nucleic acids (93). These biofilms demonstrate enhanced resilience against external challenges such as antibiotics, temperature variations, and pH fluctuations. Consequently, they pose a significant hurdle in the progression of bacterial diseases in animals. Eradicating biofilms, produced by attached bacteria, presents additional complications (94). Although most research has focused on chemical bactericidal agents to combat opportunistic infections, physical treatments like CP (specific treatment) offer an alternative approach when the efficacy of chemical agents is compromised due to the natural resistance of pathogens or biofilms (95). As microorganisms can develop resistance to certain drugs over time through genetic mutation or alterations in gene sequences, the inactivation of drug-resistant microorganisms becomes increasingly challenging compared to non-resistant ones (96). Nevertheless, numerous studies have provided evidence of the effectiveness of CP in deactivating drug-resistant microorganisms, as indicated in Table 2. Furthermore, CP has shown the ability to target biofilms formed by both gram-positive and gram-negative bacteria (74, 95, 105, 110, 111). These biofilms primarily consist of water along with extracellular polysaccharides, proteins, and DNA (112). The efficacy of CP in deactivating multidrug-resistant pathogens and biofilms varies depending on the microorganisms’ structure, composition, and resistance (98, 99). The eradication of MDR superbugs, such as the “ESKAPE” pathogens, poses a major clinical challenge in the 21st century (28). Among these pathogens is Enterococcus faecalis, a gram-positive coccus that forms biofilms, increasing its tolerance and reducing sensitivity to antimicrobial measures (113, 114). In vitro, studies have demonstrated that CP exhibits antibacterial effects against both planktonic cultures and biofilms of E. faecalis (115).

The application of CAP treatment resulted in a significant reduction of 7 log10 steps in colony forming units (CFU) on agar plates. When 24 h E. faecalis biofilms were treated with CAP, a 3 log10-step reduction in CFU was observed after 5 min of treatment. In comparison, the positive controls chlorhexidine (CHX) and UVC exhibited slightly greater effectiveness than CAP in the conducted biofilm experiments. Notably, CAP treatment did not cause damage to the cytoplasmic membrane of E. faecalis, suggesting that membrane disruption is not the primary mechanism of action against this bacterium. Moving on to P. aeruginosa, an opportunistic pathogen that causes purulent inflammation in dogs’ ears and skin, its biofilms are known to contribute to antibiotic resistance and therapeutic limitations. Therefore, the antibacterial and antibiofilm properties of cold atmospheric microwave plasma against P. aeruginosa were studied under laboratory conditions (30). The findings indicated that complete elimination of both the ATCC strain and clinical isolates of P. aeruginosa was achieved within 120 s at 50 W, with the clinical isolates requiring 60 s less than the ATCC strain for complete eradication at the same power level (83). In another study by Cao et al. (101), the effectiveness of NTP (non-thermal plasma) against E. faecalis and S. aureus suspensions on agar plates, as well as E. faecalis biofilm on nitrate membrane filters, was assessed. Following NTP treatment, inhibition zones were observed in agar cultures, and the size of these zones increased with longer treatment durations.

DBD can be effective against MRSA strains that carry the β-lactamase gene and mecA antibiotic resistance. Through DBD, penicillin-binding proteins and regulatory factors that may affect peptidoglycan (PG) are inactivated and result in decreased β-lactamase activity, which may be due to inactivation of the β-lactamase enzyme as well as its associated gene (97). In a study by Napp et al. (98), it was observed that the effect of DBD on MRSA and MSSA is different, which could be due to the stiffer cell wall of MRSA compared to MSSA, as for certain strains by Kawai et al. (116) showed an association between thickened cell wall (MRSA) and resistance to disinfectants in vitro has been documented. Additional research on the impact of CP on bacterial biofilms is presented in Table 2.

Livestock diseases often involve bacteria such as C. botulinum, C. perfringens, B. cereus, and B. subtilis. These bacterial species have developed various mechanisms to survive harsh environments, including the formation of protective spores (117). CP treatment has emerged as a promising method for inactivating bacterial spores. The primary mechanisms through which CP inactivates spores are as follows: (i) DNA damage caused by emitted UV radiation (118), (ii) erosion of the spore surface, penetration into the cortex, and damage to the spore nucleus, resulting in changes to protein structure, internal lipids, and degradation of dipicolinic acid (119), and (iii) etching of the spore coat through the action of reactive nitrogen species (RNS) (120).

Spores typically possess multi-layered outer structures that serve as the first line of defense against chemicals and physical aggression, contributing to their resistance. The external structures are primarily responsible for the spores’ resilience. Some spore species, such as B. cereus, possess an additional outermost layer called the exosporium, composed of proteins, lipids, and carbohydrates. Studies have shown that these extrinsic structures are targeted by CP for spore inactivation (121–123). For instance, in a study utilizing a helium atmosphere, CP treatment resulted in the complete rupture of B. subtilis spores, with oxidation by active plasma species identified as the primary cause of spore death (124). CP-induced damage to the spore coat leads to the release of dipicolinic acid (DPA) and increased hydration of the spore nucleus, which is a key factor in spore inactivation (125).

Multiple research studies have provided evidence that CP-generated UV photons primarily target the DNA within spores, leading to their inactivation (109, 126). Damage to the intracellular DNA can result in the death of spores. In atmospheric pressure plasma-jet (ACP-PJ), an alternative approach to increasing reactive oxygen species (ROS) production is to raise the excitation voltage, which influences energy and electron density.

In a study by Pina-Perez et al. (120), atmospheric pressure plasma-surface barrier discharge (ACP-SBD) with air as the process gas was investigated for its impact on B. subtilis spores. They achieved approximately 4 log inactivation of B. subtilis spores using a low plasma power density of 5 mW/cm² and an exposure time of 7 min. Furthermore, they demonstrated that the composition of the matrix material or food substance can influence the efficiency of B. subtilis spore inactivation. Numerous research studies have been conducted worldwide to explore the effects of CP on bacterial spores (Table 2).

The skin serves as a vital immune organ, playing a crucial role in protecting the body against pathogens and physical or chemical threats from the environment (127). Any damage to the integrity of the skin can result in significant impairment or even mortality. CP therapy, an innovative therapeutic approach, has been proposed for the treatment of extensive and chronic wounds. The selective eradication of severely damaged cells and the concurrent promotion of cell proliferation and migration stand as pivotal facets of this method. At the forefront of this technique is its remarkable capacity to generate stress-induced reactive oxygen species (ROS), a mechanism that enables the targeted elimination of compromised cells. Importantly, this selective action is achieved while ensuring the preservation of normal cells from harm. This fundamental capability of CP to eliminate bacteria without inducing injury to host tissue underscores a vital theme in this discussion. While the intricate details of ROS may be reserved for subsequent paragraphs, the overarching concept of CP’s ability to maintain a delicate balance between therapeutic efficacy and tissue well-being deserves prominence from the outset (128–130). In veterinary medicine, effective wound management is crucial to prevent permanent disability and economic burden.

The main components of CAP include ions, electrons, metastable, photons, and electromagnetic fields. After a reaction with environmental air, CAP forms a hierarchical group of reactive oxygen and nitrogen species (RONS) that promote increased skin tissue microcirculation, increased monocyte stimulation, increased cell migration, and stimulation of the keratinocytes and fibroblasts primarily involved in wound healing (131).

The potential influence of cold atmospheric plasma extends to the production of nitric oxide. Current understanding points to the significant part played by NO in healing wounds and regenerating tissues by managing blood vessel contraction and clotting, along with the immune system and early-stage cell death or apoptosis (132). External introduction of NO-donors—molecules that hold, release, or create nitric oxide when they come into contact with tissue—to a wound site can enhance and accelerate the healing process (133, 134). CAP may further contribute to wound recovery via its disinfectant properties, the stimulation of skin cell growth and movement through the activation or suppression of integrin receptors on the cell surface, or its pro-angiogenic effects (135).

A study by Amini et al. (136) showed that CAP treatment can alter the durability of inflammatory cytokines and growth factors, including IL-1, IL-8, TGF-β, TNF-α, and INF-γ, thereby facilitating healing by initiating the proliferative phase at a quicker rate. Another research piece by Arndt et al. (137) revealed that when CAP treatment was analyzed in vitro, it resulted in the heightened expression of crucial genes involved in the wound healing process, such as IL-6, IL-8, MCP-1, TGF-ß1, TGF-ß2. In addition, it boosted the production of collagen type I and alpha-SMA, which play significant roles in tissue repair. According to research conducted by Zhang et al. (138), the application of CP has been found to accelerate wound healing by reducing the healing time, decreasing wound size, and promoting wound contraction and re-epithelialization. Additionally, the study showed a significant increase in the protein level of smooth muscle actin, indicating improved wound healing.

Before the integration of plasma technologies into medical applications, a comprehensive evaluation of their impact on living tissues is imperative. This assessment extends to encompass an exploration of potential toxic effects resulting from plasma exposure. The significance of this pursuit lies not only in its scientific underpinnings but also in its direct implications for clinical practice. Indeed, the determination of safe and efficacious implementation avenues, free from the specter of long-term adverse effects, forms a pivotal cornerstone in advocating for the broader utilization of CP in the realm of veterinary medicine. By harmonizing the scientific and clinical dimensions, this approach resonates with the quest to establish a solid foundation for the expansion of CP’s applications within this critical domain. To evaluate the safety of plasma treatment on both intact and wounded skin, a Yorkshire pig model, which has comparable skin characteristics to humans, was utilized (139). The findings of the study indicated that plasma treatment is safe for both types of skin, even at doses higher than those needed for effective bacterial inactivation in agar or liquid media. Further research has focused on investigating the molecular and physiological consequences of CP treatment on mouse skin (115). The cells in the dermis and epidermis respond to reactive oxygen species (ROS) through redox signaling, which occurs due to environmental stress or disruptions in tissue homeostasis (140). Plasma-derived ROS induces changes in the junctional network, improves tissue oxygenation, oxidizes stratum corneum lipids, and limits the penetration of substances like the model drug curcumin (115).

In a study conducted by Lee et al. (141), the impact of CAP on skin physiological parameters and tolerance in dogs was assessed. The CAP treatment was applied to various points on the dogs’ natural skin in the groin area for durations of 30 s, 1 min, 2 min, and 4 min. Hydration, trans epidermal water loss (TEWL), and surface temperature were measured before and after the CAP treatment, with measurements taken five times, three times, and three times, respectively. The results showed that, except for mild erythema observed in the treatment area after 4 min, the majority of dogs did not exhibit significant pain responses or side effects. In another research study by Li et al. (142), the possible mechanisms of a cold atmospheric plasma jet on a rabbit wound infected with methicillin-resistant S. aureus (MRSA) were investigated in vivo. The researchers found that the treatment could regulate cytokine secretion, limit the inflammatory response and excessive cell proliferation, accelerate re-epithelialization, and ultimately promote the wound healing process while inactivating bacteria. Furthermore, the potential of atmospheric pressure plasma jet therapy for wound healing was studied using a mouse model of ear wounds in research conducted by Schmidt et al. (143). The effectiveness of CP on skin regeneration was explored in this study.

The in vitro experiments investigating the effect of CP on keratinocyte and fibroblast migration, specifically in the context of scratch assays, showed that CP stimulation led to significant stimulation and rapid closure of the gaps. To enhance the astringent effect of CP jets on acute wounds in mice, researchers applied microliters of distilled water to the wounds before treatment. The combined treatment of water and plasma was found to be more effective than plasma treatment alone. The water, when combined with plasma, may chemically and physically modify the wound surface, leading to enhanced wound-healing effects. These findings suggest that the combination of CP and water can potentially have synergistic effects on wound healing processes.

The study by Nakajima et al. (144) demonstrated that the combination of plasma treatment and pouring water had a significant impact on enhancing the strength of myofibroblasts. This suggests a correlation between the reduction of wound size and an increase in the number of myofibroblasts. Furthermore, the combined treatment of plasma and water pouring was more effective in promoting wound contraction compared to plasma treatment alone.

In a study conducted on New Zealand white rabbits, Alhabshan et al. (145) analyzed the effects of CAP on wound healing after corneal epithelial and basement membrane ablation. The results indicated that CAP did not hinder the rate of wound closure, induce increased inflammation, or adversely affect corneal wound healing. These findings highlight the potential of CP as a beneficial treatment for wound healing, and further research on the impact of CP on wound healing in animals can be explored in Table 3.

In veterinary medicine, there is growing interest in utilizing CP, also known as non-thermal plasma, as a promising treatment option for bacterial diseases. This innovative technology creates a plasma field that generates active species such as reactive oxygen and nitrogen species (RONS), known for their antimicrobial properties. The use of CP in animal healthcare brings various advantages, including its ability to combat bacterial infections effectively. However, there are also certain limitations and restrictions associated with its application. Despite these restrictions, CP holds great potential as an alternative treatment for bacterial diseases in veterinary medicine (59).

Advantages: safety: CP is a non-thermal process that poses no risk of heat generation, which makes it a safe option for treating animals. Unlike traditional thermal plasma, it does not harm tissues by causing thermal injury, therefore it can be used in sensitive areas such as the eye or ear. Efficacy: CP has exhibited antimicrobial properties against a broad spectrum of bacteria, including resistant strains. In veterinary medicine, it has been successfully employed to treat bacterial infections in animals, including skin and wound infections. Versatility: CP can be administered in various forms, including sprays and topical applications, rendering it a versatile treatment option for different kinds of bacterial infections. Environmental sustainability: CP does not produce hazardous waste; thus, it is an environmentally friendly alternative to traditional antibiotics. Limitations: cost: the equipment required for CP treatment can be expensive, making it a cost-prohibitive option for some veterinary practices. Lack of standardization: there is currently a lack of standardization in the field of CP treatment, making it difficult to compare the efficacy of different devices. Limited research: although CP has shown promise as a treatment option for bacterial infections in animals, further research is needed to fully understand its mechanism of action and efficacy. Regulatory approval: CP is currently not approved by regulatory agencies for the treatment of bacterial infections in animals, making it difficult for veterinary practices to use it in a clinical setting.

In conclusion, CP shows promise as a treatment option for bacterial diseases in veterinary medicine. However, more research is necessary to gain a comprehensive understanding of its mechanisms of action, effectiveness, and safety. Furthermore, the high cost of equipment and the absence of regulatory approval may restrict its widespread adoption in the field of veterinary medicine. Despite these challenges, continued exploration and development of CP technology could potentially overcome these limitations and contribute to improved treatment options for bacterial diseases in animals.

In conclusion, the use of CP in veterinary medicine for treating bacterial diseases is a promising and emerging field of research. CP has demonstrated significant potential in managing various bacterial infections in veterinary medicine, including respiratory infections, skin infections, and wound infections (36). One of the most notable advantages of implementing CP is its capability to eradicate a wide spectrum of bacteria, which includes strains that are resistant to antibiotics. Moreover, it can boost the immune system and expedite the process of wound healing. Nevertheless, CP therapy in veterinary medicine has certain limitations. Ensuring consistent and uniform exposure of the affected area to the plasma can pose a challenge and may affect its efficacy. Additionally, more research needs to be conducted to establish optimal treatment conditions, such as exposure time and plasma density, for different types of bacterial infections. Although the use of CP in veterinary medicine holds great potential, further investigation is imperative to fully comprehend its advantages and drawbacks. Future studies should concentrate on optimizing treatment protocols and assessing the long-term consequences of CP therapy on both bacterial infections and animal health.

PM and NF wrote the first draft. AG revised the manuscript. All authors contributed to the article and approved the submitted version.

This work is based upon research funded by Iran National Science Foundation (INSF) under Project No. 4015898.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.